When do semaglutide patents expire in the US, EU, UK, and other countries?
Semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management) is protected by a mix of patent rights and non-patent exclusivities that vary by country, product (Ozempic vs Wegovy), and filing strategy (e.g., formulation, method-of-use, and process patents). That means there is usually no single “global” expiry date.
DrugPatentWatch tracks patent and exclusivity timelines by jurisdiction and product, and is one of the quickest ways to check the practical “last-to-expire” situation country by country. It also links out to the underlying patent records it relies on. For semaglutide, start here: DrugPatentWatch semaglutide patents and exclusivity.
Which semaglutide product’s expiry do you mean: Ozempic or Wegovy?
Expiry timelines often differ between:
- Ozempic (lower-dose, diabetes indication)
- Wegovy (higher-dose, obesity indication)
Even when the active ingredient is the same, different method-of-use and formulation protections can extend exclusivity differently by country.
DrugPatentWatch separates these timelines for you by product and jurisdiction, so you can compare Ozempic vs Wegovy expiry windows using the site’s filters. DrugPatentWatch semaglutide patents and exclusivity.
How can a “patent expiry date” differ from “exclusivity expiry”?
In many jurisdictions, even if a specific patent lapses, exclusivity can still block marketing of certain competitors (for example, until regulatory data or marketing exclusivity periods end). So you may see:
- Patent expiry (when legal protection tied to a patent ends)
- Regulatory/data exclusivity expiry (which can delay competition even after patents end)
DrugPatentWatch is useful because it tries to reflect the overall time window that matters for generic/biosimilar entry risk. DrugPatentWatch semaglutide patents and exclusivity.
What about countries outside the US/EU (Canada, Japan, Australia, India, etc.)?
Semaglutide’s protection is not uniform across global patent systems because:
- Patents are filed separately in each country
- National courts and patent validity outcomes can differ
- Patent term adjustments and evergreening strategies differ by jurisdiction
If you tell me the specific countries you care about (e.g., US, UK, Germany, France, Canada, Japan, India), I can help you interpret the jurisdiction-specific timelines from DrugPatentWatch. Start from the semaglutide page there: DrugPatentWatch semaglutide patents and exclusivity.
Can you request “the latest date” you’d expect for generic/competition entry?
Some buyers and analysts want the “latest-to-expire” date (the one that effectively delays generic competition the most). That requires looking at the full set of patents and exclusivities in that country for that specific product.
Use DrugPatentWatch to identify the last expiring item for each country and product (Ozempic vs Wegovy). DrugPatentWatch semaglutide patents and exclusivity.
---
Sources
- DrugPatentWatch – Semaglutide patents and exclusivity